Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 7/20 | 0.72 |
| ▸ | CD99 | P14209 | 1/20 | 0.68 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.67 |
| ▸ | P2RY11 | Q96G91 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA4 | P22748 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203126 | 1.00 | NT5E (0.72) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL17202535 | 1.00 | NT5E (0.72) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL17206187 | 1.00 | NT5E (0.72) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL17213334 | 1.00 | NT5E (0.72) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL20350602 | 0.93 | NT5E (0.84) | NT5ECD99ADORA3ADORA2AADORA1 | |
| SCHEMBL17202642 | 0.91 | NT5E (0.72) | NT5ECD99P2RY1P2RY11 | |
| SCHEMBL17202646 | 0.91 | NT5E (0.72) | NT5ECD99P2RY1P2RY11 | |
| SCHEMBL17202815 | 0.91 | NT5E (0.87) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL17202524 | 0.91 | NT5E (0.87) | NT5ECD99P2RY1ADORA3P2RY11 | |
| SCHEMBL17202697 | 0.91 | NT5E (0.87) | NT5ECD99P2RY1ADORA3P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | claimed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | claimed |
| EP-3134411-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | Vitae Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | claimed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | claimed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | claimed |
| EP-3134411-B1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2021-06-30 | — | — | EP | disclosed |
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-19 | — | — | US | disclosed |
| EP-3134411-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | Vitae Pharmaceuticals, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-16 | — | — | US | disclosed |
| WO-2015164573-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654884-B2 | Purine derivatives as CD73 inhibitors for the treatment of cancer | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885CD99 1587/4885P2RY1 35/4885 |
| US-20170044203-A1 | PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER | ENTPD5, ENTPD1, NT5E | NT5E 3/4885CD99 1716/4885P2RY1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.